

RICERCA BUYS MDS PHARMA SERVICES

Ricerca Biosciences has acquired the discovery and preclinical business of MDS Pharma Services with facilities and almost 600 associates in Bothell, Washington; Lyon, France; and Taipei, Taiwan.

The expanded organisation provides the biopharmaceutical industry with access to a global contract research organization (CRO) focused on the developmental phase between intellectual property (IP) and submission of the investigational new drug (IND) application.

Ricerca chairman and chief executive officer Ian Lennox said: "With facilities worldwide combining local experience, immense scientific expertise and a strong commitment to excellent client service, we provide unique discovery and development services. Our expanded organization is a research partner clients can rely on to think strategically about projects, anticipate needs and rapidly deliver study results."

Ricerca Biosciences currently has capabilities in discovery and medicinal chemistry, API process chemistry, cGMP manufacturing and scale-up and IND-enabling toxicology. The addition of the MDS Pharma Services molecular profiling, pharmacology/DMPK and drug safety assessment services will allow Ricerca to offer a more comprehensive suite of discovery and preclinical services to support drug candidates from discovery through IND on a global scale.

MJ Insurance assisted Ricerca Biosciences in analysing additional business risk and existing and future insurance needs related to the acquisition of MDS Pharma Services. The MJ team, led by Colin MacNab, worked with its Assurex Global partners to ensure compliance and appropriate coverage for the international locations of MDS acquired by Ricerca. MJ's Life Sciences Team has also ensured that Ricerca is adequately protected for the new risk presented by MDS, and secured insurance placements for reduced costs. **fi**

Ricerca Biosciences LLC Acquires MDS Pharma Services

Legal Advisor to the Management Team:



Risk & Insurance Due Diligence Provider:



Financial Advisor to the Vendor:

**Goldman
Sachs**

Legal Due Diligence:

